5L2S

The X-ray co-crystal structure of human CDK6 and Abemaciclib.


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.27 Å
  • R-Value Free: 0.249 
  • R-Value Work: 0.206 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance.

Chen, P.Lee, N.V.Hu, W.Xu, M.Ferre, R.A.Lam, H.Bergqvist, S.Solowiej, J.Diehl, W.He, Y.A.Yu, X.Nagata, A.VanArsdale, T.Murray, B.W.

(2016) Mol.Cancer Ther. 15: 2273-2281

  • DOI: 10.1158/1535-7163.MCT-16-0300
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Therapeutically targeting aberrant intracellular kinase signaling is attractive from a biological perspective but drug development is often hindered by toxicities and inadequate efficacy. Predicting drug behaviors using cellular and animal models is ...

    Therapeutically targeting aberrant intracellular kinase signaling is attractive from a biological perspective but drug development is often hindered by toxicities and inadequate efficacy. Predicting drug behaviors using cellular and animal models is confounded by redundant kinase activities, a lack of unique substrates, and cell-specific signaling networks. Cyclin-dependent kinase (CDK) drugs exemplify this phenomenon because they are reported to target common processes yet have distinct clinical activities. Tumor cell studies of ATP-competitive CDK drugs (dinaciclib, AG-024322, abemaciclib, palbociclib, ribociclib) indicate similar pharmacology while analyses in untransformed cells illuminates significant differences. To resolve this apparent disconnect, drug behaviors are described at the molecular level. Nonkinase binding studies and kinome interaction analysis (recombinant and endogenous kinases) reveal that proteins outside of the CDK family appear to have little role in dinaciclib/palbociclib/ribociclib pharmacology, may contribute for abemaciclib, and confounds AG-024322 analysis. CDK2 and CDK6 cocrystal structures with the drugs identify the molecular interactions responsible for potency and kinase selectivity. Efficient drug binding to the unique hinge architecture of CDKs enables selectivity toward most of the human kinome. Selectivity between CDK family members is achieved through interactions with nonconserved elements of the ATP-binding pocket. Integrating clinical drug exposures into the analysis predicts that both palbociclib and ribociclib are CDK4/6 inhibitors, abemaciclib inhibits CDK4/6/9, and dinaciclib is a broad-spectrum CDK inhibitor (CDK2/3/4/6/9). Understanding the molecular components of potency and selectivity also facilitates rational design of future generations of kinase-directed drugs. Mol Cancer Ther; 15(10); 2273-81. ©2016 AACR.


    Organizational Affiliation

    Oncology Research Unit, Pfizer Worldwide Research and Development, San Diego, California.,Oncology Medicinal Chemistry, Pfizer Worldwide Research and Development, San Diego, California.,Oncology Research Unit, Pfizer Worldwide Research and Development, San Diego, California. brion.murray@pfizer.com.,Drug Safety, Pfizer Worldwide Research and Development, San Diego, California.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Cyclin-dependent kinase 6
A
307Homo sapiensMutation(s): 0 
Gene Names: CDK6 (CDKN6)
EC: 2.7.11.22
Find proteins for Q00534 (Homo sapiens)
Go to Gene View: CDK6
Go to UniProtKB:  Q00534
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
6ZV
Query on 6ZV

Download SDF File 
Download CCD File 
A
N-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-fluoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-amine
Abemaciclib
C27 H32 F2 N8
UZWDCWONPYILKI-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.27 Å
  • R-Value Free: 0.249 
  • R-Value Work: 0.206 
  • Space Group: I 4
Unit Cell:
Length (Å)Angle (°)
a = 102.170α = 90.00
b = 102.170β = 90.00
c = 59.830γ = 90.00
Software Package:
Software NamePurpose
BUSTERphasing
Aimlessdata scaling
BUSTERrefinement
autoXDSdata processing

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2016-08-24
    Type: Initial release
  • Version 1.1: 2016-10-19
    Type: Database references